|
Real-time Estimate
Cboe BZX
15:58:12 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 8.990 USD | +0.67% |
|
+0.90% | +0.30% |
Company Valuation: Xilio Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 437.3 | 73.73 | 15.14 | 41.98 | 33.61 | 58.76 | - | - |
| Change | - | -83.14% | -79.46% | 177.26% | -19.94% | 74.83% | - | - |
| Enterprise Value (EV) | 249 | -36.83 | -26.25 | -13.31 | 33.61 | 58.76 | 58.76 | 58.76 |
| Change | - | -114.79% | 28.73% | 49.29% | 352.5% | 74.83% | 0% | 0% |
| P/E | -1.18x | -0.84x | -0.2x | -0.88x | -2.14x | -3.45x | -4x | -2.8x |
| PBR | 2.37x | 0.7x | 0.41x | 2.48x | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0x | 0.1x | 0.3x | -0.1x |
| Capitalization / Revenue | - | - | - | 6.62x | 0.77x | 1.46x | 2.21x | 9.21x |
| EV / Revenue | - | - | - | -0x | 0x | 1.46x | 2.21x | 9.21x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -189.3 | -45.08 | -38.92 | -15.26 | -4.19 | -2.59 | -2.23 | -3.19 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 6.344 | 43.77 | 40.33 | 26.53 | 6.38 |
| EBITDA | -73.54 | -87.3 | -77.23 | -58.94 | - | - | - | - |
| EBIT | -75.04 | -89.15 | -79.13 | -60.58 | - | - | - | - |
| Net income 1 | -75.8 | -88.22 | -76.4 | -58.24 | -35.04 | -48.7 | -45.4 | -78.4 |
| Net Debt | -188.3 | -110.6 | -41.39 | -55.29 | - | - | - | - |
| Reference price 2 | 224.000 | 37.660 | 7.700 | 13.370 | 8.963 | 8.930 | 8.930 | 8.930 |
| Nbr of stocks (in thousands) | 1,952 | 1,958 | 1,966 | 3,140 | 3,750 | 6,580 | - | - |
| Announcement Date | 3/1/22 | 3/2/23 | 4/1/24 | 3/11/25 | 3/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.45x | - | - | - | 58.76M | |
| 31.22x | 5.63x | 16.85x | 1.04% | 45.63B | |
| -20.98x | 242.53x | -22.52x | -.--% | 43.96B | |
| 34.21x | 3.31x | 14.26x | -.--% | 43.73B | |
| 46.35x | 5.36x | 29.32x | -.--% | 40.23B | |
| 27.13x | 8.18x | 20.73x | 0.42% | 31.86B | |
| 33.86x | 5.55x | 25.2x | -.--% | 16.62B | |
| 24.06x | 2.1x | 9.08x | 1.11% | 14.46B | |
| 73.06x | 3.87x | 15.02x | -.--% | 13.04B | |
| Average | 27.27x | 34.56x | 13.49x | 0.32% | 27.73B | |
| Weighted average by Cap. | 26.40x | 46.94x | 11.98x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- XLO Stock
- Valuation Xilio Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
